全文获取类型
收费全文 | 6872篇 |
免费 | 422篇 |
国内免费 | 23篇 |
专业分类
耳鼻咽喉 | 98篇 |
儿科学 | 626篇 |
妇产科学 | 116篇 |
基础医学 | 858篇 |
口腔科学 | 132篇 |
临床医学 | 441篇 |
内科学 | 1421篇 |
皮肤病学 | 304篇 |
神经病学 | 349篇 |
特种医学 | 326篇 |
外科学 | 672篇 |
综合类 | 181篇 |
一般理论 | 3篇 |
预防医学 | 403篇 |
眼科学 | 245篇 |
药学 | 564篇 |
中国医学 | 24篇 |
肿瘤学 | 554篇 |
出版年
2023年 | 50篇 |
2022年 | 123篇 |
2021年 | 227篇 |
2020年 | 164篇 |
2019年 | 193篇 |
2018年 | 222篇 |
2017年 | 141篇 |
2016年 | 163篇 |
2015年 | 176篇 |
2014年 | 297篇 |
2013年 | 335篇 |
2012年 | 460篇 |
2011年 | 442篇 |
2010年 | 271篇 |
2009年 | 215篇 |
2008年 | 305篇 |
2007年 | 315篇 |
2006年 | 301篇 |
2005年 | 280篇 |
2004年 | 256篇 |
2003年 | 219篇 |
2002年 | 195篇 |
2001年 | 148篇 |
2000年 | 125篇 |
1999年 | 120篇 |
1998年 | 70篇 |
1997年 | 42篇 |
1996年 | 48篇 |
1995年 | 33篇 |
1994年 | 44篇 |
1993年 | 41篇 |
1992年 | 87篇 |
1991年 | 93篇 |
1990年 | 96篇 |
1989年 | 84篇 |
1988年 | 71篇 |
1987年 | 81篇 |
1986年 | 60篇 |
1985年 | 61篇 |
1984年 | 65篇 |
1983年 | 47篇 |
1982年 | 64篇 |
1981年 | 75篇 |
1980年 | 72篇 |
1979年 | 55篇 |
1978年 | 33篇 |
1977年 | 26篇 |
1976年 | 34篇 |
1973年 | 31篇 |
1970年 | 26篇 |
排序方式: 共有7317条查询结果,搜索用时 15 毫秒
91.
92.
Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference. 总被引:47,自引:0,他引:47
Noelle Sevilir Williams Richard B Gaynor Shane Scoggin Udit Verma Tunc Gokaslan Clifford Simmang Jason Fleming Denise Tavana Eugene Frenkel Carlos Becerra 《Clinical cancer research》2003,9(3):931-946
PURPOSE: The purpose of this study was to profile gene expression changes in colorectal tumors to identify new targets and strategies for the management of this disease. EXPERIMENTAL DESIGN: cDNA microarray analysis was used to detect differences in gene expression between normal tissue and colon tumors and polyps isolated from 20 patients. To identify genes that are important in regulating the growth properties of colorectal cancer, RNA interference (RNAi) was used to disrupt expression of several of the overexpressed genes in a colon tumor cell line, HCT116, which showed similar patterns of gene expression as many of the patient tumors. RESULTS: Expression changes of > or =2-fold in approximately one-third of the patients were consistently observed for 2632 of a total of 9592 genes (574 up-regulated genes and 2058 down-regulated genes). Subsequent analysis of 13 genes by quantitative real-time PCR confirmed the reliability of this analysis. RNAi-mediated disruption of the expression of one of these genes, survivin, a potent inhibitor of apoptosis, severely reduced tumor growth both in vitro and in an in vivo xenograft model. CONCLUSIONS: The combined use of microarray analysis and RNAi provides an excellent system to define the role of specific genes that are up-regulated in cancer lead to the increased in vitro and in vivo growth of colon tumors. 相似文献
93.
Francesco D’Errico Ph.D. Ravinder Nath Ph.D. Giovanni Silvano M.D. Luigi Tana D.Sc. 《International journal of radiation oncology, biology, physics》1998,41(5):1453
Purpose: A new technique is presented for in vivo measurements of the dose equivalent from photoneutrons produced by high-energy radiotherapy accelerators.Methods and Materials: The dosimeters used for this purpose are vials of superheated halocarbon droplets suspended in a tissue-equivalent gel. Neutron interactions nucleate the formation of bubbles, which can be recorded through the volume of gel they displace from the detector vials into graduated pipettes. These detectors offer inherent photon discrimination, dose-equivalent response to neutrons, passive operation, and small sensitive size. An in vivo vaginal probe was fabricated containing one of these neutron detector vials and a photon-sensitive diode. Measurements were carried out in patients undergoing high-energy x-ray radiotherapy and were also repeated in-phantom, under similar irradiation geometries.Results and Conclusion: Neutron doses of 0.02 Sv were measured in correspondence to the cervix, 50 cm from the photon beam axis, following a complete treatment course of 46.5 Gy with an upper mantle field of 18-MV x-rays. This fraction of dose from neutrons is measured reliably within an intense photon background, making the technique a valid solution to challenging dosimetry problems such as the determination of fetal exposure in radiotherapy. These measurements can be easily carried out with tissue-equivalent phantoms, as our results indicate an excellent correlation between in vivo and in-phantom dosimetry. 相似文献
94.
Expanding the living related donor pool in renal transplantation: use of marginal donors 总被引:2,自引:0,他引:2
Kumar A Mandhani A Verma BS Srivastava A Gupta A Sharma RK Bhandari M 《The Journal of urology》2000,163(1):33-36
PURPOSE: In a living related transplantation program it is not always possible to find an ideal donor. Sometimes the only available donor in the family has some benign disease or suboptimal renal anatomy or physiology, or is too old to be accepted and defined as a marginal donor. However, with proper screening the donor pool can be increased by accepting these marginal donors and treating the benign diseases which is beneficial to the donor. We evaluate the outcome of grafts from marginal donors. MATERIALS AND METHODS: From July 1988 to August 1997, 581 live related transplantations were performed. Of the donors 52 were older than 60 years and 34 had associated benign renal or nonrenal anomaly or disease. These donors were accepted after thorough questioning and consultation with family members. The recipients of graft from elderly donors were evaluated for the number of rejections, serum creatinine at last followup and graft survival. RESULTS: Of the recipients 52 received grafts from elderly donors with a mean age of 62.6+/-3.7 years. Mean followup was 34.14+/-0.7 months. The 2 and 5-year actuarial graft survival was 96% and 74%, respectively. Creatinine was normal (less than 1.5) in 37% of recipients and 1.5 to 2.5 mg.% in 46%. The rejection rate in postoperative month 1 was 29%. All donors underwent simultaneous surgery to treat the benign disease, and all did well after surgery. CONCLUSIONS: By accepting these marginal donors a 14.6% increase in the living related donor pool was achieved without compromising recipient or donor safety. Otherwise these recipients would have been forced to undergo unrelated transplantation or be maintained on dialysis, which is particularly difficult in a developing country. Donors with associated disease benefited from cure. 相似文献
95.
Verma S Lovren F Dumont AS Mather KJ Maitland A Kieser TM Triggle CR Anderson TJ 《The Journal of thoracic and cardiovascular surgery》2000,120(4):668-671
OBJECTIVES: Diminished production of nitric oxide has been linked to saphenous vein endothelial dysfunction. Tetrahydrobiopterin is an obligate cofactor for the oxidation of L -arginine by nitric oxide synthase in the production of nitric oxide by endothelial cells. The objective of the present study was to examine whether the exogenous addition of tetrahydrobiopterin improves endothelial function in saphenous veins from patients undergoing coronary artery bypass graft operations. METHODS: Vascular segments of saphenous veins were obtained from 17 patients undergoing elective coronary artery bypass grafting, and in vitro endothelium-dependent and endothelium-independent responses to acetylcholine and sodium nitroprusside were assessed. Isometric dose-response curves were constructed in precontracted rings in the presence and absence of tetrahydrobiopterin (0.1 mmol/L) with the use of the organ bath apparatus. The percentages of maximum relaxation and sensitivity were compared between interventions. RESULTS: Acetylcholine caused dose-dependent endothelium-mediated relaxation in saphenous veins. In the presence of tetrahydrobiopterin, acetylcholine-induced relaxation was significantly augmented (percentage maximum relaxation, 16.8% +/- 2.9% vs control 7.5% +/- 1.8%; P =.003) without an effect on agonist sensitivity. These effects were endothelium-specific because endothelium-independent responses to sodium nitroprusside were preserved. CONCLUSIONS: These data uncover beneficial effects of acute tetrahydrobiopterin addition on endothelial function in human vessels. Because endothelial dysfunction has been implicated in the development of graft failure, studies aimed at chronic delivery of tetrahydrobiopterin would be useful in determining the contribution of this cofactor toward saphenous vein atherosclerosis. 相似文献
96.
97.
Charles Butts Nevin Murray Andrew Maksymiuk Glenwood Goss Ernie Marshall Denis Soulières Yvon Cormier Peter Ellis Allan Price Ravinder Sawhney Mary Davis Janine Mansi Colum Smith Dimitrios Vergidis Paul Ellis Mary MacNeil Martin Palmer 《Journal of clinical oncology》2005,23(27):6674-6681
PURPOSE: To evaluate the effect of BLP25 liposome vaccine (L-BLP25) on survival and toxicity in patients with stage IIIB and IV non-small-cell lung cancer (NSCLC). Secondary objectives included health-related quality of life (QOL) and immune responses elicited by L-BLP25. PATIENTS AND METHODS: Patients with an Eastern Cooperative Oncology Group performance status of 0 to 2 and stable or responding stage IIIB or IV NSCLC after any first-line chemotherapy were prestratified by stage and randomly assigned to either L-BLP25 plus best supportive care (BSC) or BSC alone. Patients in the L-BLP25 arm received a single intravenous dose of cyclophosphamide 300 mg/m2 followed by eight weekly subcutaneous immunizations with L-BLP25 (1,000 microg). Subsequent immunizations were administered at 6-week intervals. RESULTS: The survival results indicate a median survival time of 4.4 months longer for patients randomly assigned to the L-BLP25 arm (88 patients) compared with patients assigned to the BSC arm (83 patients; adjusted hazard ratio [HR] = 0.739; 95% CI, 0.509 to 1.073; P = .112). The greatest effect was observed in stage IIIB locoregional (LR) patients, for whom the median survival time for the L-BLP25 arm has not yet been reached compared with 13.3 months for the BSC arm (adjusted HR = 0.524; 95% CI, 0.261 to 1.052; P = .069). No significant toxicity was observed. QOL was maintained longer in patients on the L-BLP25 arm. CONCLUSION: L-BLP25 maintenance therapy in patients with advanced NSCLC is feasible with minimal toxicity. The survival difference of 4.4 months observed with the vaccine did not reach statistical significance. In the subgroup of patients with stage IIIB LR disease, a strong trend in 2-year survival in favor of L-BLP25 was observed. 相似文献
98.
Development and evaluation of osmotically controlled oral drug delivery system of glipizide. 总被引:6,自引:0,他引:6
Rajan K Verma Sanjay Garg 《European journal of pharmaceutics and biopharmaceutics》2004,57(3):513-525
Extended release formulation of glipizide based on osmotic technology was developed and evaluated. The effect of different formulation variables, namely, level of solubility modifier in the core, membrane weight gain, and level of pore former in the membrane, were studied. Drug release was found to be affected by the level of solubility modifier in the core formulation. Glipizide release was inversely proportional to the membrane weight but directly related to the initial level of pore former (PVP) in the membrane. Burst strength of the exhausted shells increased with the weight gain of the membrane. On the other hand, burst strength decreased with an increase in the level of pore former in the membrane. Drug release from the developed formulations was independent of pH and agitational intensity, but dependent on the osmotic pressure of the release media. Results of SEM studies showed the formation of pores in the membrane from where the drug release occurred. The numbers of pores were directly proportional to the initial level of pore former in the membrane. The manufacturing procedure was found to be reproducible and formulations were stable after 3 months of accelerated stability studies. 相似文献
99.
Gurjeet Dulku Ravinder Dhillon Mark Goodwin Wendy Cheng Nick Kontorinis Richard Mendelson 《Journal of Medical Imaging and Radiation Oncology》2017,61(2):171-179
A decision support tool has been developed as part of a suite of on‐line evidence‐based and consensus‐based guidelines Diagnostic imaging Pathways (DIP): www.imagingpathways.health.wa.gov.au ) in the form of an algorithmic flow chart with supporting evidence and consensus to inform referrers to diagnostic imaging and radiologists as to the optimum strategy for surveillance and diagnosis of primary hepatocellular cancer (HCC) in those patients with risk factors of this disease. A literature review, including reference to several international consensus‐based expert guidelines, has been employed to develop this tool. 相似文献